National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
About National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.
By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. NCCN programs offer access to expert physicians, superior treatment, and quality and safety initiatives that continuously improve the effectiveness and efficiency of cancer care globally.
NCCN 20th Anniversary Video - Improving Cancer Care Together
January 31, 2015 marked the 20th anniversary of the National Comprehensive Cancer Network; originally announced as an alliance of 13 leading cancer centers in 1995, NCCN has grown to a network of 26 academic cancer centers devoted to patient care, research, and education.
Featuring past and present leadership, this video describes the groundbreaking accomplishments of NCCN over the past two decades that have improved the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
120 articles with National Comprehensive Cancer Network
New NCCN Guidelines Debut to Manage Complications and Improve Readiness for Stem Cell Transplant Recipients
National Comprehensive Cancer Network expands resources to meet growing utilization of cell-based cancer treatments
National Comprehensive Cancer Network Oncology Research Program Supports Clinical Trial for Lung Cancer
Phase II randomized trial led by investigators at Fox Chase Cancer Center will look at chemotherapy combinations for people with stage IV non-squamous non-small cell lung cancer with EGFR mutation or who never smoked
Flatiron Assist™ to Integrate Clinical Decision Support Tools Within Oncology Workflows
Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients, According to New Study
Research from the O'Neal Comprehensive Cancer Center at UAB finds patients treated outside of NCCN Guidelines recommendations had significantly higher direct costs
International Collaboration to Improve Cancer Care in Sub-Saharan Africa Announces Management of Most Adult Cancers Covered by NCCN Harmonized Guidelines
A collaborative project from the National Comprehensive Cancer Network®, the African Cancer Coalition, the American Cancer Society, and others to improve cancer outcomes in Sub-Saharan Africa enters a new phase in Addis Ababa, Ethiopia.
NCCN Updates Spanish Adaptations of NCCN Guidelines to Enable Better Cancer Prevention, Diagnosis, and Treatment in Spain
New and improved mobile app and upcoming NCCN Global Academy event reflect the organization's efforts to increase worldwide access to NCCN resources. #NCCNGlobal
New NCCN Guidelines Are First to Address Small Intestine Cancers; Updates Highlight Developments in Genetic Testing and Hereditary Risk for Colon and Other Intestinal Cancers
New NCCN Guidelines for Small Bowel Adenocarcinoma are first clinical guidelines in the United States to address this rare but growing cancer type, which is sometimes associated with hereditary causes like Lynch syndrome
BTG plc, the global healthcare company, highlighted the first publication of National Comprehensive Cancer Network pediatric acute lymphoblastic leukemia guidelines including consideration of Voraxaze®.
New NCCN Guidelines for Patients: Bladder Cancer explains the lengthy surveillance process that follows active treatment for the sixth most-common cancer in the United States.
NCCN Advances Cancer Research and Oncology Career Development with Young Investigator Awards, Poster Presentations, and Fellows Program
The National Comprehensive Cancer Network supports cancer research and treatment through various programs during and after the NCCN 2019 Annual Conference.
Agency Clarifies CDC Guideline Not Meant to Limit Access to Appropriate Pain Management for Individuals with Cancer, Sickle Cell Disease
NCCN 2019 Annual Conference Addresses How to Improve Cancer Care Worldwide Amid Intersecting Public Health Crises
Oncology professionals from all over the world met in Orlando to discuss how to better address the needs of people with cancer. Join the conversation online with the hashtag #NCCNac19
National Comprehensive Cancer Network Recognizes Five Individuals for Outstanding Achievements in Improving Cancer Care
National Comprehensive Cancer Network® (NCCN®) today announced the recipients of a series of awards honoring individuals whose significant contributions fueled progress in improving and facilitating quality, effective, efficient, and accessible cancer care over the past year.
Dr. Walters elected chair of the Board of the alliance of leading cancer centers; UW Carbone's Ruth O'Regan elected Vice-Chair
NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology
The quality improvement studies will focus on methods of intervention that can be implemented across a variety of different oncology practice settings.
BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the NCCN Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal
Array BioPharma Inc. announced that the National Comprehensive Cancer Network® has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI® in combination with MEKTOVI® and an anti-EGFR antibody as a Category 2a treatment for patients with BRAFV600E-mutant metastatic colorectal cancer, after failure of one or two prior lines of therapy for metastatic disease.
The studies will be funded through a collaboration between the NCCN Oncology Research Program and Taiho Oncology, Inc. to investigate the effectiveness of trifluridine and tipiracil
New NCCN Guidelines for Patients: Squamous Cell Skin Cancer explains risk factors and treatment options for cancer type that impacts millions every year.
Integrating Heart Disease and Cancer Care Could Reduce Overall Health Care Costs, According to Researchers
Study in JNCCN finds coronary artery disease costs increase dramatically in patients who are diagnosed with cancer
National Comprehensive Cancer Network Updates Resources for Improving Cancer Care in the Middle East & North Africa
NCCN Adaptations updated to streamline care and encourage best practices for cancer treatment in the MENA region